Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 5
Treatment-assignment count: 0
Stratification count: 0
NSCLC · Immune Checkpoint Inhibitor
NTRK fusion is flagged as trial selection rising because public trials show inclusion required evidence in 5 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 5
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 5
Common snippets: MET exon 14 skipping | KRAS G12C | KRAS G12C
Threshold label: Moderate
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT06364917 | https://clinicaltrials.gov/study/NCT07111520 | https://clinicaltrials.gov/study/NCT07285434 | https://clinicaltrials.gov/study/NCT06119581 | https://clinicaltrials.gov/study/NCT06711900